CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
BI 765080 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04666922
NCT04666922Phase 1Completed
CompareCT.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Intravenous Doses of BI 765080 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel-group Design)

Boehringer Ingelheim·interventional·Posted Dec 14, 2020·Updated Feb 23, 2024

In Brief

A Phase 1 clinical trial evaluating BI 765080 and Placebo for Healthy. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 765080 in healthy male subjects following intravenous administration of single rising doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedDec 14, 2020
Enrollment StartJan 14, 2021
Primary CompletionAug 25, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.5 years ago

Interventions

BI 765080drug

BI 765080

Placebodrug

Placebo; 0.9% saline for injection